抗纤Ⅰ号抗肝纤维化的临床研究

Clinical Study on the Treatment of Hepatic Fibrosis by"Antifibrosis-Ⅰ Decoction

为观察复方中药抗纤Ⅰ号治疗肝硬化的临床疗效。选择 12 0例乙肝后肝硬化活动期患者 ,随机分为 3组 ,各 4 0例 ,中西医结合组 (A组 )予中药抗纤 1号联合甘利欣治疗 ;中药组 (B组 )单纯予中药抗纤Ⅰ号治疗 ;对照组 (C组 )予甘利欣加口服安慰剂治疗。疗程均为 3个月。观察治疗前后肝功能、血清肝纤维化指标、HBV -DNA以及B超测定门静脉、脾静脉内径和脾脏厚径。结果 :3组患者治疗后在症状、体征和肝功能方面均有明显改善。A组和B组在降低血清肝纤维化指标 ,缩小门静脉、脾静脉内径和脾脏厚径方面 ,较C组差异有显著性意义 (P <0 0 5 )。且A组疗效明显优于B组和C组。提示抗纤Ⅰ号可能具有控制肝细胞炎症 ,降低门脉压力 ,以及抗肝纤维化的作用。

To observe the clinical efficacy of 'Antifibrosis Ⅰ Decoction' in the treatment of hepatic fibrosis,120 cases of liver cirrhosis were equally randomized into three groups:group A in which the Decoction and Diammonium Glycyrrhizinate were given,group B in which the Decoction was given and group C in which the Diammonium Glycyrrhizinate was given,all with a course of three months.The liver function,serum indexes of hepatic fibrosis and HBV DNA were assayed,and inner diameter of portal vein and spleen vein as well as the thickness of the spleen were measured by B ultrasonography before and after treatment.Results:After treatment,the clinical symptoms,signs and liver functions were all improved;group A and group B had better effects than group C in reducing the serum indexes,narrowing the inner diameter of portal vein,spleen vein and the thickness of the spleen( P <0 05),also with better effects in group A than in group B.